Equities research analysts at Dougherty & Co started coverage on shares of Irhythm Technologies (NASDAQ:IRTC) in a note issued to investors on Friday, Marketbeat Ratings reports. The firm set a “neutral” rating on the stock.

Several other research analysts also recently commented on the stock. Canaccord Genuity restated a “buy” rating and set a $59.00 price objective on shares of Irhythm Technologies in a research report on Tuesday, November 14th. Morgan Stanley boosted their price objective on shares of Irhythm Technologies from $50.00 to $65.00 and gave the company an “overweight” rating in a research report on Friday, November 3rd. ValuEngine raised shares of Irhythm Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, October 21st. Finally, Zacks Investment Research cut shares of Irhythm Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Irhythm Technologies has an average rating of “Hold” and an average target price of $60.67.

Shares of Irhythm Technologies (IRTC) traded down $2.15 on Friday, reaching $53.35. 263,447 shares of the company’s stock traded hands, compared to its average volume of 263,114. Irhythm Technologies has a 1-year low of $24.25 and a 1-year high of $57.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.65 and a quick ratio of 7.57.

Irhythm Technologies (NASDAQ:IRTC) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.05. Irhythm Technologies had a negative net margin of 27.56% and a negative return on equity of 27.67%. The business had revenue of $25.04 million during the quarter, compared to the consensus estimate of $24.30 million. During the same period in the previous year, the business earned ($2.80) earnings per share. The company’s revenue was up 49.2% on a year-over-year basis. sell-side analysts anticipate that Irhythm Technologies will post -1.17 earnings per share for the current fiscal year.

In other Irhythm Technologies news, Director Vijay K. Lathi sold 225,000 shares of the business’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $52.10, for a total transaction of $11,722,500.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Kevin M. King sold 60,000 shares of the business’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $51.85, for a total transaction of $3,111,000.00. Following the sale, the insider now directly owns 103,042 shares in the company, valued at approximately $5,342,727.70. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 337,362 shares of company stock worth $17,403,035. Insiders own 23.30% of the company’s stock.

Several institutional investors have recently modified their holdings of IRTC. FMR LLC grew its stake in shares of Irhythm Technologies by 382.2% in the second quarter. FMR LLC now owns 1,542,886 shares of the company’s stock worth $65,557,000 after purchasing an additional 1,222,886 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Irhythm Technologies by 103.2% in the second quarter. Capital Research Global Investors now owns 2,399,180 shares of the company’s stock worth $101,941,000 after purchasing an additional 1,218,580 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of Irhythm Technologies by 644.3% in the second quarter. Alliancebernstein L.P. now owns 883,986 shares of the company’s stock worth $37,561,000 after purchasing an additional 765,218 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Irhythm Technologies by 2,702.1% in the second quarter. Bank of New York Mellon Corp now owns 607,054 shares of the company’s stock worth $25,794,000 after purchasing an additional 585,390 shares during the last quarter. Finally, Marshall Wace North America L.P. bought a new stake in shares of Irhythm Technologies in the second quarter worth $21,300,000. 97.83% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Dougherty & Co Initiates Coverage on Irhythm Technologies (IRTC)” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/01/dougherty-co-initiates-coverage-on-irhythm-technologies-irtc.html.

Irhythm Technologies Company Profile

iRhythm Technologies, Inc is a United States-based digital health company. The Company develops and commercializes solutions that integrate biosensor technology, patient data, analytics and medical expertise. The Company offers flagship solution, the ZIO Service. Its ZIO Service consists of the ZIO XT Patch, algorithms and the ZIO Report.

Receive News & Ratings for Irhythm Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.